Stock Track | Alnylam Pharmaceuticals Soars 6.25% in Pre-Market on Strong Q1 Earnings Beat and Revenue Growth

Stock Track

Apr 30

Alnylam Pharmaceuticals' stock surged 6.25% in pre-market trading following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.

The biopharmaceutical company reported adjusted earnings per share of $1.99, beating the consensus estimate of $0.93 by 113.98% and representing a 586.21% increase from the same period last year. Quarterly sales reached $1.167 billion, surpassing the $1.114 billion estimate by 4.79% and marking a 96.40% year-over-year growth.

Additionally, Alnylam Pharmaceuticals reiterated its full-year 2026 financial guidance, reinforcing investor confidence in the company's ongoing performance and future prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1181637019"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181637019\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181637019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181637019","market":"sg","top_or_hot":-1,"title":"Stock Track | Alnylam Pharmaceuticals Soars 6.25% in Pre-Market on Strong Q1 Earnings Beat and Revenue Growth","media":"Stock Track","content":"<p>Alnylam Pharmaceuticals' stock surged 6.25% in pre-market trading following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.</p><p>The biopharmaceutical company reported adjusted earnings per share of $1.99, beating the consensus estimate of $0.93 by 113.98% and representing a 586.21% increase from the same period last year. Quarterly sales reached $1.167 billion, surpassing the $1.114 billion estimate by 4.79% and marking a 96.40% year-over-year growth.</p><p>Additionally, Alnylam Pharmaceuticals reiterated its full-year 2026 financial guidance, reinforcing investor confidence in the company's ongoing performance and future prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alnylam Pharmaceuticals Soars 6.25% in Pre-Market on Strong Q1 Earnings Beat and Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alnylam Pharmaceuticals Soars 6.25% in Pre-Market on Strong Q1 Earnings Beat and Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-30 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alnylam Pharmaceuticals' stock surged 6.25% in pre-market trading following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.</p><p>The biopharmaceutical company reported adjusted earnings per share of $1.99, beating the consensus estimate of $0.93 by 113.98% and representing a 586.21% increase from the same period last year. Quarterly sales reached $1.167 billion, surpassing the $1.114 billion estimate by 4.79% and marking a 96.40% year-over-year growth.</p><p>Additionally, Alnylam Pharmaceuticals reiterated its full-year 2026 financial guidance, reinforcing investor confidence in the company's ongoing performance and future prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"","article_id":"1181637019","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181637019","pubTimestamp":1777550837,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Alnylam Pharmaceuticals' stock surged 6.25% in pre-market trading following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司"},"translate_title":"个股追踪|Alnylam Pharmaceuticals盘前飙升6.25%，因Q1盈利超预期和营收增长强劲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1},"content_text":"Alnylam Pharmaceuticals' stock surged 6.25% in pre-market trading following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.The biopharmaceutical company reported adjusted earnings per share of $1.99, beating the consensus estimate of $0.93 by 113.98% and representing a 586.21% increase from the same period last year. Quarterly sales reached $1.167 billion, surpassing the $1.114 billion estimate by 4.79% and marking a 96.40% year-over-year growth.Additionally, Alnylam Pharmaceuticals reiterated its full-year 2026 financial guidance, reinforcing investor confidence in the company's ongoing performance and future prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}